Switzerland· 66808002
Trelegy Ellipta, Einzeldosiertes Pulver zur Inhalation
A vilanterol, umeclidinium bromid und fluticason furoat product containing fluticasoni furoas, umeclidinium, vilanterolum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Vilanterol, umeclidinium bromid und fluticason furoat is registered in 11 of 19 countries.
Countries holding a registration under ATC R03AL08 (vilanterol, umeclidinium bromid und fluticason furoat), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Vilanterol, umeclidinium bromid und fluticason furoat · ATC R03AL08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- fluticasoni furoas, umeclidinium, vilanterolum
- Manufacturer
- GlaxoSmithKline AG
- Country
- Switzerland (CH)
- ATC code
- R03AL08
- ATC class
- Vilanterol, Umeclidinium bromid und Fluticason furoat
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806680800213 x 30 DosenCHF 197.55
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vilanterol, umeclidinium bromid und fluticason furoat in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- United KingdomTrelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhalerGlaxoSmithKline UK Ltd
- SpainELEBRATO ELLIPTA 92 MICROGRAMOS/55 MICROGRAMOS/22 MICROGRAMOS POLVO PARA INHALACION (UNIDOSIS)Glaxosmithkline Trading Services Limited
- SwedenElebrato Ellipta 92 mikrogram/55 mikrogram/22 mikrogram Inhalationspulver, avdelad dosGlaxoSmithKline Trading Services Ltd
- PolandElebrato ElliptaGlaxoSmithKline Trading Services Limited
- CanadaTRELEGY ELLIPTAGLAXOSMITHKLINE INC
- NorwayTrelegy ElliptaGlaxoSmithKline Trading Services Limited
- IrelandTrelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elebrato Ellipta, Trelegy Ellipta
- Liechtenstein · Elebrato Ellipta, Trelegy Ellipta
- Norway · Elebrato Ellipta, Trelegy Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bbd49f83-a0f0-410a-9684-50298552c20c GET /v1/drugs/bbd49f83-a0f0-410a-9684-50298552c20c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "fluticasoni furoas 92 mcg + umeclidinium 55 mcg + vilanterolum 22 mcg",
"valid_from": "2019-01-01",
"limitations": "[{\"description\":\"Für Patienten mit moderater COPD nach ≥ 1 Exazerbation trotz einer mindestens 3 Monate dauernder optimierter Therapie unter LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/µl, welche nicht ausreichend eingestellt sind<br>\\n<b>oder</b><br>\\nfür Patienten mit moderater bis schwerer COPD nach ≥ 2 moderaten Exazerbationen oder 1 Exazerbation, welche zu einer Hospitalisation geführt hat trotz einer mindestens 3 Monaten dauernden optimierter Therapie unter ICS/LABA oder LABA/LAMA (für LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/µl), welche nicht ausreichend eingestellt sind<br>\\n<b>oder</b><br>\\nfür Patienten mit COPD, welche bereits mit einer Kombination von LABA/LAMA und ICS oder ICS/LABA und LAMA mit mehreren Inhalatoren therapiert werden.<br>\\n<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-01-01\"}]",
"galenic_form": "Inh Plv 92/55/22mcg",
"therapeutic_area": null,
"sl_inclusion_date": "2019-01-01",
"self_retention_pct": 10
}See everything about vilanterol, umeclidinium bromid und fluticason furoat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.